Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspt189dxw

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	26	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	27	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	28	JUN 19	CAS REGISTRY includes selected substances from web-based collections

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

```
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 20:53:41 ON 20 JUN 2008

=> index bioscience
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
       AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
       CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
       DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 20:53:49 ON 20 JUN 2008

69 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s lactoperoxidase and osteo?
          1   FILE AGRICOLA
          9   FILE BIOSIS
          1   FILE BIOTECHABS
          1   FILE BIOTECHDS
          2   FILE BIOTECHNO
          3   FILE CABA
         13   FILE CAPLUS
  22 FILES SEARCHED...
          1   FILE DGENE
          2   FILE DRUGU
         10   FILE EMBASE
          2   FILE ESBIOBASE
          3   FILE FROSTI
          3   FILE FSTA
          4   FILE IFIPAT
          2   FILE LIFESCI
          5   FILE MEDLINE
          1   FILE PASCAL
          2   FILE PROMT
          5   FILE SCISEARCH
          3   FILE TOXCENTER
  60 FILES SEARCHED...
        587   FILE USPATFULL
         97   FILE USPAT2
          8   FILE WPIDS
          8   FILE WPINDEX

  24 FILES HAVE ONE OR MORE ANSWERS,   69 FILES SEARCHED IN STNINDEX

L1   QUE LACTOPEROXIDASE AND OSTEO?
```

```
=> s l1 and (food or drink or drug or feed)
          1   FILE BIOSIS
          1   FILE BIOTECHNO
          1   FILE CABA
          5   FILE CAPLUS
          1   FILE DGENE
          1   FILE DRUGU
  27 FILES SEARCHED...
          7   FILE EMBASE
          1   FILE FSTA
          2   FILE IFIPAT
          1   FILE MEDLINE
          2   FILE PROMT
          1   FILE SCISEARCH
          1   FILE TOXCENTER
  59 FILES SEARCHED...
        475   FILE USPATFULL
         84   FILE USPAT2
          6   FILE WPIDS
          6   FILE WPINDEX

  17 FILES HAVE ONE OR MORE ANSWERS,   69 FILES SEARCHED IN STNINDEX

L2   QUE L1 AND (FOOD OR DRINK OR DRUG OR FEED)

=> file biosis biotechno caba caplus dgene drugu embase fsta ifipat medline promt
scisearch toxcenter uspatfull uspat2
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                   2.60       2.81

FILE 'BIOSIS' ENTERED AT 20:56:16 ON 20 JUN 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'BIOTECHNO' ENTERED AT 20:56:16 ON 20 JUN 2008
COPYRIGHT (C) 2008 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 20:56:16 ON 20 JUN 2008
COPYRIGHT (C) 2008 CAB INTERNATIONAL (CABI)

FILE 'CAPLUS' ENTERED AT 20:56:16 ON 20 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 20:56:16 ON 20 JUN 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'DRUGU' ENTERED AT 20:56:16 ON 20 JUN 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'EMBASE' ENTERED AT 20:56:16 ON 20 JUN 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'FSTA' ENTERED AT 20:56:16 ON 20 JUN 2008
COPYRIGHT (C) 2008 International Food Information Service

FILE 'IFIPAT' ENTERED AT 20:56:16 ON 20 JUN 2008
COPYRIGHT (C) 2008 IFI CLAIMS(R) Patent Services (IFI)

FILE 'MEDLINE' ENTERED AT 20:56:16 ON 20 JUN 2008
```

FILE 'PROMT' ENTERED AT 20:56:16 ON 20 JUN 2008

FILE 'SCISEARCH' ENTERED AT 20:56:16 ON 20 JUN 2008

FILE 'TOXCENTER' ENTERED AT 20:56:16 ON 20 JUN 2008

FILE 'USPATFULL' ENTERED AT 20:56:16 ON 20 JUN 2008

FILE 'USPAT2' ENTERED AT 20:56:16 ON 20 JUN 2008

=> s l2
L3 584 L2

=> rem dup l3
DUP IS NOT VALID HERE
The DELETE command is used to remove various items stored by the system.

To delete a saved query, saved answer set, saved L-number list, SDI request, batch request, mailing list, or user-defined cluster, format, or search field, enter the name. The name may include ? for left, right, or simultaneous left and right truncation.

Examples:

```
  DELETE BIO?/Q          - delete query names starting with BIO
  DELETE ?DRUG/A         - delete answer set names ending with DRUG
  DELETE ?ELEC?/L        - delete L-number lists containing ELEC
  DELETE ANTICOAG/S      - delete SDI request
  DELETE ENZYME/B        - delete batch request
  DELETE .MYCLUSTER      - delete user-defined cluster
  DELETE .MYFORMAT       - delete user-defined display format
  DELETE .MYFIELD        - delete user-defined search field
  DELETE NAMELIST MYLIST - delete mailing list
```

To delete an ordered document or an offline print, enter its number.

Examples:

```
  DELETE P123001C        - delete print request
  DELETE D134002C        - delete document order request
```

To delete an individual L-number or range of L-numbers, enter the L-number or L-number range. You may also enter DELETE LAST followed by a number, n, to delete the last n L-numbers. RENUMBER or NORENUMBER may also be explicitly specified to override the value of SET RENUMBER.

Examples:

```
  DELETE L21             - delete a single L-number
  DELETE L3-L6           - delete a range of L-numbers
  DELETE LAST 4          - delete the last 4 L-numbers
  DELETE L33-            - delete L33 and any higher L-number
  DELETE -L55            - delete L55 and any lower L-number
```

```
  DELETE L2-L6 RENUMBER - delete a range of L-numbers and
                          renumber remaining L-numbers
  DELETE RENUMBER       - renumber L-numbers after deletion of
                          intermediate L-numbers

Entire sets of saved items, SDI requests, batch requests, user-defined
items, or E-numbers can be deleted.

Examples:

  DELETE SAVED/Q - delete all saved queries
  DELETE SAVED/A - delete all saved answer sets
  DELETE SAVED/L - delete all saved L-number lists
  DELETE SAVED   - delete all saved queries, answer sets,
                   and L-number lists
  DELETE SAVED/S - delete all SDI requests
  DELETE SAVED/B - delete all batch requests
  DELETE CLUSTER - delete all user-defined clusters
  DELETE FORMAT  - delete all user-defined display formats
  DELETE FIELD   - delete all user-defined search fields
  DELETE SELECT  - delete all E-numbers
  DELETE HISTORY - delete all L-numbers and restart the
                   session at L1

To delete an entire multifile SDI request, enter DELETE and
the name of the request.  To delete a component from the
multifile SDI, enter DELETE and the name of the component.

=> dup rem l3
DUPLICATE IS NOT AVAILABLE IN 'DGENE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L3
L4          581 DUP REM L3 (3 DUPLICATES REMOVED)

=> s l4 and digest?
L5         474 L4 AND DIGEST?

=> s l5 and osteoblast?
L6         107 L5 AND OSTEOBLAST?

=> s l6 and promot?
L7         103 L6 AND PROMOT?

=> s l7 and induc?
L8          98 L7 AND INDUC?

=> s l8 and osteogenesis
L9          28 L8 AND OSTEOGENESIS

=> d l9 1-28

L9   ANSWER 1 OF 28  USPATFULL on STN
AN     2008:137337  USPATFULL
TI     Osteoblast Growth Factor
IN     Phan, Tuan, Success, AUSTRALIA
       Xu, Jiake, Karrinyup, AUSTRALIA
       Zheng, Ming Hao, City Beach, AUSTRALIA
PI     US 20080119406      A1  20080522
AI     US 2005-587218      A1  20050413 (11)
       WO 2005-AU526           20050413
                               20070813  PCT 371 date
PRAI   AU 2004-2004902048  20040419
```

DT Utility
FS APPLICATION
LN.CNT 2550
INCL INCLM: 514/012.000
INCLS: 514/013.000; 514/014.000; 514/015.000
NCL NCLM: 514/012.000
NCLS: 514/013.000; 514/014.000; 514/015.000
IC IPCI A61K0038-00 [I,A]; A61P0019-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 2 OF 28 USPATFULL on STN
AN 2007:334990 USPATFULL
TI HUMAN CDNAS AND PROTEINS AND USES THEREOF
IN BEJANIN, STEPHANE, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PI US 20070292885 A1 20071220
AI US 2007-831468 A1 20070731 (11)
RLI Continuation of Ser. No. US 2004-838854, filed on 3 May 2004, GRANTED, Pat. No. US 7291495 Division of Ser. No. US 2001-489, filed on 14 Nov 2001, GRANTED, Pat. No. US 6794363 Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, GRANTED, Pat. No. US 7074901
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 26802
INCL INCLM: 435/006.000
INCLS: 435/320.100; 435/325.000; 435/069.100; 435/007.100; 530/300.000; 530/387.900; 536/023.100
NCL NCLM: 435/006.000
NCLS: 435/007.100; 435/069.100; 435/320.100; 435/325.000; 530/300.000; 530/387.900; 536/023.100
IC IPCI C12Q0001-68 [I,A]; C07H0021-00 [I,A]; C07K0016-00 [I,A]; C07K0002-00 [I,A]; G01N0033-53 [I,A]; C12N0015-63 [I,A]; C12N0005-00 [I,A]; C12P0021-00 [I,A]
IPCR C12Q0001-68 [I,C]; C12Q0001-68 [I,A]; C07H0021-00 [I,C]; C07H0021-00 [I,A]; C07K0002-00 [I,C]; C07K0002-00 [I,A]; C07K0016-00 [I,C]; C07K0016-00 [I,A]; C12N0005-00 [I,C]; C12N0005-00 [I,A]; C12N0015-63 [I,C]; C12N0015-63 [I,A]; C12P0021-00 [I,C]; C12P0021-00 [I,A]; G01N0033-53 [I,C]; G01N0033-53 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 28 USPATFULL on STN
AN 2007:48142 USPATFULL
TI WISP polypeptides and nucleic acids encoding same
IN Botstein, David, Belmont, CA, UNITED STATES
Cohen, Robert L., San Mateo, CA, UNITED STATES
Goddard, Audrey D., San Francisco, CA, UNITED STATES
Gurney, Austin L., Belmont, CA, UNITED STATES
Hillan, Kenneth J., San Francisco, CA, UNITED STATES
Lawrence, David A., San Francisco, CA, UNITED STATES
Levine, Arnold J., New York, NY, UNITED STATES
Pennica, Diane, Burlingame, CA, UNITED STATES
Roy, Margaret Ann, San Francisco, CA, UNITED STATES
Wood, William I., Hillsborough, CA, UNITED STATES
PI US 20070041964 A1 20070222
AI US 2006-488375 A1 20060717 (11)
RLI Division of Ser. No. US 2002-112267, filed on 27 Mar 2002, GRANTED, Pat.

No. US 7101850 Division of Ser. No. US 1998-182145, filed on 29 Oct 1998, GRANTED, Pat. No. US 6387657
PRAI US 1997-63704P 19971029 (60)
US 1998-73612P 19980204 (60)
US 1998-81695P 19980414 (60)
DT Utility
FS APPLICATION
LN.CNT 9316
INCL INCLM: 424/131.100
INCLS: 424/146.100; 530/387.200; 530/388.260
NCL NCLM: 424/131.100
NCLS: 424/146.100; 530/387.200; 530/388.260
IC IPCI A61K0039-395 [I,A]; C07K0016-40 [I,A]; C07K0016-42 [I,A]
IPCR A61K0039-395 [I,C]; A61K0039-395 [I,A]; C07K0016-40 [I,C]; C07K0016-40 [I,A]; C07K0016-42 [I,C]; C07K0016-42 [I,A]

L9 ANSWER 4 OF 28 USPATFULL on STN
AN 2006:247698 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA Serono Genetics Institute S.A., Evry, FRANCE (non-U.S. corporation)
PI US 20060211090 A1 20060921
AI US 2006-412325 A1 20060427 (11)
RLI Division of Ser. No. US 2002-154678, filed on 22 May 2002, PENDING
Continuation-in-part of Ser. No. US 2001-924340, filed on 6 Aug 2001, GRANTED, Pat. No. US 7074901
PRAI US 2001-293574P 20010525 (60)
US 2001-298698P 20010615 (60)
US 2001-302277P 20010629 (60)
US 2001-305456P 20010713 (60)
DT Utility
FS APPLICATION
LN.CNT 20353
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC IPCI C07K0014-47 [I,A]; C07K0014-435 [I,C*]; C07H0021-04 [I,A]; C07H0021-00 [I,C*]; C12P0021-06 [I,A]
IPCR C07K0014-435 [I,C]; C07K0014-47 [I,A]; G01N0033-50 [I,C*]; G01N0033-50 [I,A]; A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0045-00 [I,C*]; A61K0045-00 [I,A]; A61K0048-00 [N,C*]; A61K0048-00 [N,A]; A61P0035-00 [I,C*]; A61P0035-00 [I,A]; A61P0035-02 [I,A]; A61P0035-04 [I,A]; A61P0043-00 [I,C*]; A61P0043-00 [I,A]; C07H0021-00 [I,C]; C07H0021-04 [I,A]; C07K0016-18 [I,C*]; C07K0016-18 [I,A]; C12N0015-09 [I,C*]; C12N0015-09 [I,A]; C12N0015-12 [I,C*]; C12N0015-12 [I,A]; C12P0021-02 [I,C*]; C12P0021-02 [I,A]; C12P0021-06 [I,C]; C12P0021-06 [I,A]; C12Q0001-68 [I,C*]; C12Q0001-68 [I,A]; G01N0033-15 [I,C*]; G01N0033-15 [I,A]; G01N0033-53 [I,C*]; G01N0033-53 [I,A]; G01N0033-566 [I,C*]; G01N0033-566 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 28 USPATFULL on STN
AN 2006:144853 USPATFULL
TI Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
IN McCarthy, Sean A., San Diego, CA, UNITED STATES
Gearing, David P., Camberwell, AUSTRALIA
Holtzman, Douglas A., Seattle, WA, UNITED STATES

Pan, Yang, Bellevue, WA, UNITED STATES
Busfield, Samantha J., Victoria Park, AUSTRALIA
Barnes, Thomas M., Brookline, MA, UNITED STATES
Mackay, Charles R., Vaucluse, AUSTRALIA
Lora, Jose M., Mountain View, CA, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 20060122373 A1 20060608
AI US 2005-175714 A1 20050705 (11)
RLI Continuation-in-part of Ser. No. US 2003-417719, filed on 17 Apr 2003, ABANDONED Continuation of Ser. No. US 2000-568218, filed on 9 May 2000, ABANDONED Continuation-in-part of Ser. No. US 1997-872855, filed on 11 Jun 1997, GRANTED, Pat. No. US 6121045 Continuation-in-part of Ser. No. US 1997-832633, filed on 4 Apr 1997, ABANDONED Continuation-in-part of Ser. No. US 2004-895676, filed on 21 Jul 2004, PENDING Continuation of Ser. No. US 2002-105934, filed on 25 Mar 2002, ABANDONED Continuation of Ser. No. US 2001-862972, filed on 22 May 2001, ABANDONED Continuation of Ser. No. US 1998-62389, filed on 17 Apr 1998, ABANDONED Continuation-in-part of Ser. No. US 2002-95407, filed on 11 Mar 2002, ABANDONED Continuation of Ser. No. US 1999-451828, filed on 30 Nov 1999, ABANDONED Division of Ser. No. US 1998-128155, filed on 3 Aug 1998, GRANTED, Pat. No. US 6117654 Continuation-in-part of Ser. No. US 2002-126560, filed on 19 Apr 2002, ABANDONED Continuation-in-part of Ser. No. US 1999-237571, filed on 26 Jan 1999, ABANDONED Continuation-in-part of Ser. No. US 1998-13810, filed on 27 Jan 1998, GRANTED, Pat. No. US 6197551 Continuation-in-part of Ser. No. US 2003-413899, filed on 14 Apr 2003, PENDING Division of Ser. No. US 2001-940240, filed on 27 Aug 2001, ABANDONED Continuation of Ser. No. US 1999-248239, filed on 10 Feb 1999, ABANDONED Continuation-in-part of Ser. No. US 1998-23664, filed on 10 Feb 1998, ABANDONED Continuation-in-part of Ser. No. US 2002-105150, filed on 25 Mar 2002, ABANDONED Continuation of Ser. No. US 2002-60680, filed on 30 Jan 2002, ABANDONED Continuation of Ser. No. US 1998-57951, filed on 9 Apr 1998, ABANDONED Continuation-in-part of Ser. No. US 2003-601368, filed on 23 Jun 2003, ABANDONED Continuation of Ser. No. US 2000-572003, filed on 15 May 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-561263, filed on 27 Apr 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-322790, filed on 28 May 1999, ABANDONED
PRAI US 1997-62017P 19971010 (60)
US 1997-44746P 19970418 (60)
US 1997-54646P 19970804 (60)
US 1998-91650P 19980702 (60)
DT Utility
FS APPLICATION
LN.CNT 16556
INCL INCLM: 530/350.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.500
NCL NCLM: 530/350.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.500
IC IPCI C07K0014-705 [I,A]; C07K0014-715 [I,A]; C07K0014-435 [I,C*]; C07H0021-04 [I,A]; C07H0021-00 [I,C*]; C12P0021-06 [I,A]
IPCR C07K0014-435 [I,C]; C07K0014-705 [I,A]; C07H0021-00 [I,C]; C07H0021-04 [I,A]; C07K0014-715 [I,A]; C12P0021-06 [I,C]; C12P0021-06 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 6 OF 28 USPATFULL on STN
AN 2005:30751 USPATFULL
TI Human CDNAS and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PI US 20050026182 A1 20050203
US 7291495 B2 20071106

AI US 2004-838854 A1 20040503 (10)
RLI Division of Ser. No. US 2001-489, filed on 14 Nov 2001, GRANTED, Pat. No. US 6794363 Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 25707
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/184.000; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/226.000; 435/006.000
NCLS: 435/070.100; 435/071.100; 435/252.300; 435/252.330; 435/254.100; 435/320.100; 435/325.000; 435/069.100; 435/184.000; 536/023.200
IC [7]
ICM C12Q001-68
ICS C07H021-04; C12N009-99
IPCI C12Q0001-68 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*]; C12N0009-99 [ICS,7]
IPCI-2 C12N0009-64 [I,A]; C12N0015-63 [I,A]; C12N0001-20 [I,A]; C12N0015-00 [I,A]; C12N0001-15 [I,A]; C12P0021-00 [I,A]
IPCR C12N0009-64 [I,C]; C12N0009-64 [I,A]; A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0048-00 [N,C*]; A61K0048-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-47 [I,A]; C12N0001-15 [I,C]; C12N0001-15 [I,A]; C12N0001-20 [I,C]; C12N0001-20 [I,A]; C12N0015-00 [I,C]; C12N0015-00 [I,A]; C12N0015-63 [I,C]; C12N0015-63 [I,A]; C12P0021-00 [I,C]; C12P0021-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 7 OF 28 USPATFULL on STN
AN 2004:66006 USPATFULL
TI DNA array sequence selection
IN Lorenz, Matthias, Bethesda, MD, United States
PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)
PI US 6706867 B1 20040316
AI US 2000-741238 20001219 (9)
DT Utility
FS GRANTED
LN.CNT 23532
INCL INCLM: 536/023.100
INCLS: 536/024.320; 536/024.310; 536/024.300; 435/006.000
NCL NCLM: 536/023.100
NCLS: 435/006.000; 536/024.300; 536/024.310; 536/024.320
IC [7]
ICM C07H021-04
ICS C12Q001-68
IPCI C07H0021-04 [ICM,7]; C07H0021-00 [ICM,7,C*]; C12Q0001-68 [ICS,7]
IPCR C12Q0001-68 [I,C*]; C12Q0001-68 [I,A]
EXF 435/6; 536/24.32; 536/24.31; 536/24.33; 536/23.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 8 OF 28 USPATFULL on STN
AN 2003:282611 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
PI US 20030198954 A1 20031023

```
       US 7122629          B2  20061017
AI     US 2001-1142        A1  20011114 (10)
RLI    Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI   WO 2001-IB1715      20010806
       US 2001-305456P     20010713 (60)
       US 2001-302277P     20010629 (60)
       US 2001-298698P     20010615 (60)
       US 2001-293574P     20010525 (60)
DT     Utility
FS     APPLICATION
LN.CNT 25681
INCL   INCLM: 435/006.000
       INCLS: 536/023.200
NCL    NCLM:  530/350.000; 435/006.000
       NCLS:  435/007.100; 536/023.200
IC     [7]
       ICM    C12Q001-68
       ICS    C07H021-04
       IPCI   C12Q0001-68 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*]
       IPCI-2 C07K0001-00 [I,A]; C07K0014-00 [I,A]; C07K0017-00 [I,A]
       IPCR   C07K0001-00 [I,C]; C07K0001-00 [I,A]; A61K0038-00 [N,C*];
              A61K0038-00 [N,A]; A61K0048-00 [N,C*]; A61K0048-00 [N,A];
              C07K0014-00 [I,C]; C07K0014-00 [I,A]; C07K0014-435 [I,C*];
              C07K0014-47 [I,A]; C07K0017-00 [I,C]; C07K0017-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9   ANSWER 9 OF 28  USPATFULL on STN
AN     2003:264778  USPATFULL
TI     Morphogen analogs of bone morphogenic proteins
IN     Keck, Peter C., Millbury, MA, UNITED STATES
       Bosukonda, Dattatreyamurty, Shrewsbury, MA, UNITED STATES
PA     Curis, Inc., Cambridge, MA (U.S. corporation)
PI     US 20030185792      A1  20031002
AI     US 2002-164279      A1  20020606 (10)
RLI    Continuation-in-part of Ser. No. US 2001-791946, filed on 22 Feb 2001,
       PENDING Continuation of Ser. No. US 1997-786284, filed on 22 Jan 1997,
       GRANTED, Pat. No. US 6273598 Continuation-in-part of Ser. No. US
       1996-589552, filed on 22 Jan 1996, ABANDONED
PRAI   US 2002-354820P     20020205 (60)
       US 2002-371298P     20020410 (60)
       US 2001-296291P     20010606 (60)
DT     Utility
FS     APPLICATION
LN.CNT 4870
INCL   INCLM: 424/085.100
       INCLS: 514/009.000; 514/044.000; 514/012.000; 435/184.000
NCL    NCLM:  424/085.100
       NCLS:  435/184.000; 514/009.000; 514/012.000; 514/044.000
IC     [7]
       ICM    A61K038-19
       ICS    A61K038-18; A61K038-12; A61K048-00; C12N009-99
       IPCI   A61K0038-19 [ICM,7]; A61K0038-18 [ICS,7]; A61K0038-12 [ICS,7];
              A61K0048-00 [ICS,7]; C12N0009-99 [ICS,7]
       IPCR   C07K0001-00 [I,C*]; C07K0001-00 [I,A]; C07K0014-435 [I,C*];
              C07K0014-51 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9   ANSWER 10 OF 28  USPATFULL on STN
AN     2003:244219  USPATFULL
TI     Human cDNAs and proteins and uses thereof
IN     Bejanin, Stephane, Paris, FRANCE
       Tanaka, Hiroaki, Antony, FRANCE
```

PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
PI US 20030170628 A1 20030911
US 7094876 B2 20060822
AI US 2001-999570 A1 20011114 (9)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 25549
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/007.100; 435/320.100; 435/325.000; 530/350.000; 530/388.100; 536/023.500
NCL NCLM: 530/350.000; 435/006.000
NCLS: 435/007.100; 435/069.100; 435/320.100; 435/325.000; 530/388.100; 536/023.500
IC [7]
ICM C12Q001-68
ICS G01N033-53; C07H021-04; C12P021-02; C12N005-06; C07K014-47
IPCI C12Q0001-68 [ICM,7]; G01N0033-53 [ICS,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*]; C12P0021-02 [ICS,7]; C12N0005-06 [ICS,7]; C07K0014-47 [ICS,7]; C07K0014-435 [ICS,7,C*]
IPCI-2 C07K0001-00 [I,A]; C07K0014-00 [I,A]; C07K0017-00 [I,A]
IPCR A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0048-00 [N,C*]; A61K0048-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-47 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 11 OF 28 USPATFULL on STN
AN 2003:231986 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
PI US 20030162186 A1 20030828
US 20070015144 A9 20070118
AI US 2002-154678 A1 20020522 (10)
PRAI US 2001-293574P 20010525 (60)
US 2001-298698P 20010615 (60)
US 2001-302277P 20010629 (60)
US 2001-305456P 20010713 (60)
DT Utility
FS APPLICATION
LN.CNT 25533
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM C12Q001-68
ICS C07H021-04; C12N009-00; C12P021-02; C12N005-06
IPCI C12Q0001-68 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*]; C12N0009-00 [ICS,7]; C12P0021-02 [ICS,7]; C12N0005-06 [ICS,7]
IPCI-2 C12Q0001-68 [I,A]; C07H0021-04 [I,A]; C07H0021-00 [I,C*]; C12N0009-00 [I,A]; C12P0021-02 [I,A]; C12N0005-06 [I,A]
IPCR C12Q0001-68 [I,C]; C12Q0001-68 [I,A]; A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0048-00 [N,C*]; A61K0048-00 [N,A]; C07H0021-00 [I,C]; C07H0021-04 [I,A]; C07K0014-435 [I,C*]; C07K0014-47 [I,A]; C12N0005-06 [I,C]; C12N0005-06 [I,A]; C12N0009-00 [I,C]; C12N0009-00 [I,A]; C12P0021-02 [I,C];

C12P0021-02 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 12 OF 28 USPATFULL on STN
AN 2003:225673 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
PI US 20030157485 A1 20030821
US 6989262 B2 20060124
AI US 2001-992095 A1 20011113 (9)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 25484
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 435/226.000; 800/008.000; 536/023.200; 530/388.260; 435/007.200
NCL NCLM: 435/226.000; 435/006.000
NCLS: 424/094.640; 435/041.000; 435/068.100; 435/252.300; 435/007.200; 435/069.100; 435/320.100; 435/325.000; 530/388.260; 536/023.200; 800/008.000
IC [7]
ICM C12Q001-68
ICS G01N033-53; G01N033-567; A01K067-00; C07H021-04; C12N009-64; C12P021-02; C12N005-06
IPCI C12Q0001-68 [ICM,7]; G01N0033-53 [ICS,7]; G01N0033-567 [ICS,7]; A01K0067-00 [ICS,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*]; C12N0009-64 [ICS,7]; C12P0021-02 [ICS,7]; C12N0005-06 [ICS,7]
IPCI-2 C12N0009-64 [I,A]; C12N0001-20 [I,A]; C12P0001-00 [I,A]; C12P0021-06 [I,A]; A61K0038-48 [I,A]; A61K0038-43 [I,C*]
IPCR A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0048-00 [N,C*]; A61K0048-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-47 [I,A]; C12N0009-64 [I,A]; A61K0038-43 [I,C]; A61K0038-48 [I,A]; C12N0001-20 [I,C]; C12N0001-20 [I,A]; C12N0009-64 [I,C]; C12P0001-00 [I,C]; C12P0001-00 [I,A]; C12P0021-06 [I,C]; C12P0021-06 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 13 OF 28 USPATFULL on STN
AN 2003:140406 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 20030096247 A1 20030522
US 7005500 B2 20060228
AI US 2001-986 A1 20011114 (10)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION

LN.CNT 25656
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200; 800/008.000
NCL NCLM: 530/350.000; 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200; 800/008.000
IC [7]
ICM C12Q001-68
ICS A01K067-00; C07H021-04; C12N009-00; C12P021-02; C12N005-06
IPCI C12Q0001-68 [ICM,7]; A01K0067-00 [ICS,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*]; C12N0009-00 [ICS,7]; C12P0021-02 [ICS,7]; C12N0005-06 [ICS,7]
IPCI-2 A61K0038-00 [I,A]
IPCR A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0048-00 [N,C*]; A61K0048-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-47 [I,A]; A61K0038-00 [I,A]; A61K0038-00 [I,C]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 14 OF 28 USPATFULL on STN
AN 2003:133926 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 20030092011 A1 20030515
US 6794363 B2 20040921
AI US 2001-489 A1 20011114 (10)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 25607
INCL INCLM: 435/006.000
INCLS: 800/003.000; 435/007.900; 435/183.000; 435/069.100; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 514/012.000; 435/006.000
NCLS: 435/023.000; 530/350.000; 536/023.500; 435/007.900; 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200; 800/003.000
IC [7]
ICM C12Q001-68
ICS G01N033-53; G01N033-542; C07H021-04; C12N009-00; C12P021-02; C12N005-06
IPCI C12Q0001-68 [ICM,7]; G01N0033-53 [ICS,7]; G01N0033-542 [ICS,7]; G01N0033-536 [ICS,7,C*]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*]; C12N0009-00 [ICS,7]; C12P0021-02 [ICS,7]; C12N0005-06 [ICS,7]
IPCI-2 C12Q0001-37 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*]; C07K0014-00 [ICS,7]; A61K0038-00 [ICS,7]
IPCR A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0048-00 [N,C*]; A61K0048-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-47 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 15 OF 28 USPATFULL on STN
AN 2003:99573 USPATFULL
TI WISP polypeptides and nucleic acids encoding same
IN Levine, Arnold J., Princeton, NJ, UNITED STATES
Pennica, Diane, Burlingame, CA, UNITED STATES

PA Genentech, Inc. (U.S. corporation)
PI US 20030068678 A1 20030410
US 7101850 B2 20060905
AI US 2002-112267 A1 20020327 (10)
RLI Division of Ser. No. US 1998-182145, filed on 29 Oct 1998, GRANTED, Pat. No. US 6387657
PRAI US 1997-63704P 19971029 (60)
US 1998-73612P 19980204 (60)
US 1998-81695P 19980414 (60)
DT Utility
FS APPLICATION
LN.CNT 9734
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 536/023.500; 435/183.000
NCL NCLM: 514/012.000; 435/069.100
NCLS: 530/350.000; 435/183.000; 435/320.100; 435/325.000; 536/023.500
IC [7]
ICM C07H021-04
ICS C12N009-00; C12P021-02; C12N005-06
IPCI C07H0021-04 [ICM,7]; C07H0021-00 [ICM,7,C*]; C12N0009-00 [ICS,7]; C12P0021-02 [ICS,7]; C12N0005-06 [ICS,7]
IPCI-2 A61K0038-00 [I,A]
IPCR C07H0021-00 [I,C*]; C07H0021-04 [I,A]; C12N0001-16 [I,C*]; C12N0001-16 [I,A]; C12N0001-21 [I,C*]; C12N0001-21 [I,A]; C12N0005-06 [I,C*]; C12N0005-06 [I,A]; C12N0005-16 [I,C*]; C12N0005-16 [I,A]; C12N0009-00 [I,C*]; C12N0009-00 [I,A]; C12N0015-12 [I,C*]; C12N0015-12 [I,A]; C12N0015-63 [I,C*]; C12N0015-63 [I,A]; C12P0021-02 [I,C*]; C12P0021-02 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 16 OF 28 USPATFULL on STN
AN 2003:37603 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 20030027248 A1 20030206
US 7074901 B2 20060711
AI US 2001-924340 A1 20010806 (9)
PRAI US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 25650
INCL INCLM: 435/069.100
INCLS: 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200; 435/006.000
NCL NCLM: 530/356.000; 435/069.100
NCLS: 530/324.000; 435/006.000; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
IC [7]
ICM C12P021-02
ICS C12Q001-68; C07H021-04; C12N009-00; C12N005-06
IPCI C12P0021-02 [ICM,7]; C12Q0001-68 [ICS,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*]; C12N0009-00 [ICS,7]; C12N0005-06 [ICS,7]
IPCI-2 C07K0014-78 [I,A]; C07K0014-435 [I,C*]
IPCR A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0048-00 [N,C*]; A61K0048-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-47 [I,A]; C07K0014-435 [I,C]; C07K0014-78 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 17 OF 28 USPATFULL on STN
AN 2003:37516 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
    Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 20030027161 A1 20030206
    US 7074571 B2 20060711
AI US 2001-992600 A1 20011113 (9)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
    US 2001-305456P 20010713 (60)
    US 2001-302277P 20010629 (60)
    US 2001-298698P 20010615 (60)
    US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 25529
INCL INCLM: 435/006.000
    INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000;
           536/023.200; 800/008.000
NCL NCLM: 435/007.100; 435/006.000
    NCLS: 435/069.100; 435/071.100; 435/183.000; 435/212.000; 435/219.000;
           530/350.000; 530/412.000; 530/413.000; 435/320.100; 435/325.000;
           536/023.200; 800/008.000
IC [7]
    ICM C12Q001-68
    ICS A01K067-00; C07H021-04; C12N009-00; C12P021-02; C12N005-06
    IPCI C12Q0001-68 [ICM,7]; A01K0067-00 [ICS,7]; C07H0021-04 [ICS,7];
           C07H0021-00 [ICS,7,C*]; C12N0009-00 [ICS,7]; C12P0021-02 [ICS,7];
           C12N0005-06 [ICS,7]
    IPCI-2 G01N0033-53 [I,A]; C07K0014-435 [I,A]; C12N0009-12 [I,A]
    IPCR A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0048-00 [N,C*];
           A61K0048-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-47 [I,A];
           G01N0033-53 [I,A]; C07K0014-435 [I,C]; C07K0014-435 [I,A];
           C12N0009-12 [I,C]; C12N0009-12 [I,A]; G01N0033-53 [I,C]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 18 OF 28 USPATFULL on STN
AN 2002:108847 USPATFULL
TI WISP polypeptides and nucleic acids encoding same
IN Botstein, David A., Belmont, CA, United States
    Cohen, Robert L., San Mateo, CA, United States
    Goddard, Audrey D., San Francisco, CA, United States
    Gurney, Austin L., Belmont, CA, United States
    Hillan, Kenneth J., San Francisco, CA, United States
    Lawrence, David A., San Francisco, CA, United States
    Levine, Arnold J., New York, NY, United States
    Pennica, Diane, Burlingame, CA, United States
    Roy, Margaret Ann, San Francisco, CA, United States
    Wood, William I., Hillsborough, CA, United States
PA Genentech, Inc., South San Francisco, CA, United States (U.S.
    corporation)
PI US 6387657 B1 20020514
AI US 1998-182145 19981029 (9)
PRAI US 1997-63704P 19971029 (60)
    US 1998-73612P 19980204 (60)
    US 1998-81695P 19980414 (60)
DT Utility
FS GRANTED
LN.CNT 5473

INCL INCLM: 435/069.100
INCLS: 435/069.400; 435/325.000; 435/358.000; 435/243.000; 435/252.330; 435/255.100; 435/320.100; 536/023.100; 536/023.500; 536/023.510
NCL NCLM: 435/069.100
NCLS: 435/069.400; 435/243.000; 435/252.330; 435/255.100; 435/320.100; 435/325.000; 435/358.000; 536/023.100; 536/023.500; 536/023.510
IC [7]
ICM C12N015-12
ICS C12N015-63; C12N001-21; C12N005-16; C12N001-16
IPCI C12N0015-12 [ICM,7]; C12N0015-63 [ICS,7]; C12N0001-21 [ICS,7]; C12N0005-16 [ICS,7]; C12N0001-16 [ICS,7]
IPCR C07H0021-00 [I,C*]; C07H0021-04 [I,A]; C12N0001-16 [I,C*]; C12N0001-16 [I,A]; C12N0001-21 [I,C*]; C12N0001-21 [I,A]; C12N0005-06 [I,C*]; C12N0005-06 [I,A]; C12N0005-16 [I,C*]; C12N0005-16 [I,A]; C12N0009-00 [I,C*]; C12N0009-00 [I,A]; C12N0015-12 [I,C*]; C12N0015-12 [I,A]; C12N0015-63 [I,C*]; C12N0015-63 [I,A]; C12P0021-02 [I,C*]; C12P0021-02 [I,A]
EXF 435/69.1; 435/69.4; 435/243; 435/320.1; 435/325; 435/358; 435/252.33; 435/255.1; 536/23.1; 536/23.5; 536/23.51
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 19 OF 28 USPAT2 on STN
AN 2005:30751 USPAT2
TI β-Secretase variant
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA Serono Genetics Institute S.A., Evry, FRANCE (non-U.S. corporation)
PI US 7291495 B2 20071106
AI US 2004-838854 20040503 (10)
RLI Division of Ser. No. US 2001-489, filed on 14 Nov 2001, Pat. No. US 6794363 Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, Pat. No. US 7074901
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS GRANTED
LN.CNT 25533
INCL INCLM: 435/226.000
INCLS: 435/320.100; 435/252.300; 435/252.330; 435/325.000; 435/254.100; 435/070.100; 435/071.100
NCL NCLM: 435/226.000; 435/006.000
NCLS: 435/070.100; 435/071.100; 435/252.300; 435/252.330; 435/254.100; 435/320.100; 435/325.000; 435/069.100; 435/184.000; 536/023.200
IC IPCI C12Q0001-68 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*]; C12N0009-99 [ICS,7]
IPCI-2 C12N0009-64 [I,A]; C12N0015-63 [I,A]; C12N0001-20 [I,A]; C12N0015-00 [I,A]; C12N0001-15 [I,A]; C12P0021-00 [I,A]
IPCR C12N0009-64 [I,C]; C12N0009-64 [I,A]; A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0048-00 [N,C*]; A61K0048-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-47 [I,A]; C12N0001-15 [I,C]; C12N0001-15 [I,A]; C12N0001-20 [I,C]; C12N0001-20 [I,A]; C12N0015-00 [I,C]; C12N0015-00 [I,A]; C12N0015-63 [I,C]; C12N0015-63 [I,A]; C12P0021-00 [I,C]; C12P0021-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 20 OF 28 USPAT2 on STN
AN 2003:282611 USPAT2
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE

```
       Tanaka, Hiroaki, Antony, FRANCE
PA     Serono Genetics Institute SA, FRANCE (non-U.S. corporation)
PI     US 7122629          B2  20061017
AI     US 2001-1142            20011114 (10)
RLI    Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI   WO 2001-IB1715      20010806
       US 2001-305456P     20010713 (60)
       US 2001-302277P     20010629 (60)
       US 2001-298698P     20010615 (60)
       US 2001-293574P     20010525 (60)
DT     Utility
FS     GRANTED
LN.CNT 25455
INCL   INCLM: 530/350.000
       INCLS: 514/012.000; 435/007.100
NCL    NCLM:  530/350.000; 435/006.000
       NCLS:  435/007.100; 536/023.200
IC     IPCI   C12Q0001-68 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*]
       IPCI-2 C07K0001-00 [I,A]; C07K0014-00 [I,A]; C07K0017-00 [I,A]
       IPCR   C07K0001-00 [I,C]; C07K0001-00 [I,A]; A61K0038-00 [N,C*];
              A61K0038-00 [N,A]; A61K0048-00 [N,C*]; A61K0048-00 [N,A];
              C07K0014-00 [I,C]; C07K0014-00 [I,A]; C07K0014-435 [I,C*];
              C07K0014-47 [I,A]; C07K0017-00 [I,C]; C07K0017-00 [I,A]
EXF    530/350; 514/12; 435/7.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9   ANSWER 21 OF 28  USPAT2 on STN
AN     2003:244219  USPAT2
TI     Human cDNAs and proteins and uses thereof
IN     Bejanin, Stephane, Paris, FRANCE
       Tanaka, Hiroaki, Antony, FRANCE
PA     Serono Genetics Institute SA, FRANCE (non-U.S. corporation)
PI     US 7094876          B2  20060822
AI     US 2001-999570          20011114 (9)
RLI    Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI   WO 2001-IB1715      20010806
       US 2001-305456P     20010713 (60)
       US 2001-302277P     20010629 (60)
       US 2001-298698P     20010615 (60)
       US 2001-293574P     20010525 (60)
DT     Utility
FS     GRANTED
LN.CNT 25345
INCL   INCLM: 530/350.000
NCL    NCLM:  530/350.000; 435/006.000
       NCLS:  435/007.100; 435/069.100; 435/320.100; 435/325.000; 530/388.100;
              536/023.500
IC     IPCI   C12Q0001-68 [ICM,7]; G01N0033-53 [ICS,7]; C07H0021-04 [ICS,7];
              C07H0021-00 [ICS,7,C*]; C12P0021-02 [ICS,7]; C12N0005-06 [ICS,7];
              C07K0014-47 [ICS,7]; C07K0014-435 [ICS,7,C*]
       IPCI-2 C07K0001-00 [I,A]; C07K0014-00 [I,A]; C07K0017-00 [I,A]
       IPCR   A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0048-00 [N,C*];
              A61K0048-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-47 [I,A]
EXF    530/350; 514/12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9   ANSWER 22 OF 28  USPAT2 on STN
AN     2003:231986  USPAT2
TI     Human cDNAs and proteins and uses thereof
IN     Bejanin, Stephane, Paris, FRANCE
       Tanaka, Hiroaki, Antony, FRANCE
PA     GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
```

PI US 20070015144 A9 20070118
AI US 2002-154678 A1 20020522 (10)
RLI Continuation-in-part of Ser. No. US 2001-924340, filed on 6 Aug 2001, GRANTED, Pat. No. US 7074901
PRAI US 2001-293574P 20010525 (60)
US 2001-298698P 20010615 (60)
US 2001-302277P 20010629 (60)
US 2001-305456P 20010713 (60)
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 25373
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200
IC IPCI C12Q0001-68 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*]; C12N0009-00 [ICS,7]; C12P0021-02 [ICS,7]; C12N0005-06 [ICS,7]
IPCI-2 C12Q0001-68 [I,A]; C07H0021-04 [I,A]; C07H0021-00 [I,C*]; C12N0009-00 [I,A]; C12P0021-02 [I,A]; C12N0005-06 [I,A]
IPCR C12Q0001-68 [I,C]; C12Q0001-68 [I,A]; A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0048-00 [N,C*]; A61K0048-00 [N,A]; C07H0021-00 [I,C]; C07H0021-04 [I,A]; C07K0014-435 [I,C*]; C07K0014-47 [I,A]; C12N0005-06 [I,C]; C12N0005-06 [I,A]; C12N0009-00 [I,C]; C12N0009-00 [I,A]; C12P0021-02 [I,C]; C12P0021-02 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 23 OF 28 USPAT2 on STN
AN 2003:225673 USPAT2
TI Plasmin variants and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA Serono Genetics Institute, S.A., FRANCE (non-U.S. corporation)
PI US 6989262 B2 20060124
AI US 2001-992095 20011113 (9)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS GRANTED
LN.CNT 25376
INCL INCLM: 435/226.000
INCLS: 435/252.300; 435/041.000; 435/068.100; 424/094.640
NCL NCLM: 435/226.000; 435/006.000
NCLS: 424/094.640; 435/041.000; 435/068.100; 435/252.300; 435/007.200; 435/069.100; 435/320.100; 435/325.000; 530/388.260; 536/023.200; 800/008.000
IC IPCI C12Q0001-68 [ICM,7]; G01N0033-53 [ICS,7]; G01N0033-567 [ICS,7]; A01K0067-00 [ICS,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*]; C12N0009-64 [ICS,7]; C12P0021-02 [ICS,7]; C12N0005-06 [ICS,7]
IPCI-2 C12N0009-64 [I,A]; C12N0001-20 [I,A]; C12P0001-00 [I,A]; C12P0021-06 [I,A]; A61K0038-48 [I,A]; A61K0038-43 [I,C*]
IPCR A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0048-00 [N,C*]; A61K0048-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-47 [I,A]; C12N0009-64 [I,A]; A61K0038-43 [I,C]; A61K0038-48 [I,A];

```
              C12N0001-20 [I,C]; C12N0001-20 [I,A]; C12N0009-64 [I,C];
              C12P0001-00 [I,C]; C12P0001-00 [I,A]; C12P0021-06 [I,C];
              C12P0021-06 [I,A]
EXF     435/226; 435/252.3; 435/41; 435/68.1; 424/94.64; 536/23.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9   ANSWER 24 OF 28  USPAT2 on STN
AN      2003:140406  USPAT2
TI      Human cDNAs and proteins and uses thereof
IN      Bejanin, Stephane, Paris, FRANCE
        Tanaka, Hiroaki, Antony, FRANCE
PA      Serono Genetics Institute, Inc., FRANCE (non-U.S. corporation)
PI      US 7005500          B2  20060228
AI      US 2001-986             20011114 (10)
RLI     Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI    WO 2001-IB1715      20010806
        US 2001-305456P     20010713 (60)
        US 2001-302277P     20010629 (60)
        US 2001-298698P     20010615 (60)
        US 2001-293574P     20010525 (60)
DT      Utility
FS      GRANTED
LN.CNT 25585
INCL    INCLM: 530/350.000
NCL     NCLM:  530/350.000; 435/006.000
        NCLS:  435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200;
               800/008.000
IC      IPCI   C12Q0001-68 [ICM,7]; A01K0067-00 [ICS,7]; C07H0021-04 [ICS,7];
               C07H0021-00 [ICS,7,C*]; C12N0009-00 [ICS,7]; C12P0021-02 [ICS,7];
               C12N0005-06 [ICS,7]
        IPCI-2 A61K0038-00 [I,A]
        IPCR   A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0048-00 [N,C*];
               A61K0048-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-47 [I,A];
               A61K0038-00 [I,A]; A61K0038-00 [I,C]
EXF     530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9   ANSWER 25 OF 28  USPAT2 on STN
AN      2003:133926  USPAT2
TI      Isolated amyloid inhibitor protein (APIP) and compositions thereof
IN      Bejanin, Stephane, Paris, FRANCE
        Tanaka, Hiroaki, Antony, FRANCE
PA      Genset S.A., FRANCE (non-U.S. corporation)
PI      US 6794363          B2  20040921
AI      US 2001-489             20011114 (10)
RLI     Division of Ser. No. US 2001-924340, filed on 6 Aug 2001
PRAI    US 2001-305456P     20010713 (60)
        US 2001-302277P     20010629 (60)
        US 2001-298698P     20010615 (60)
        US 2001-293574P     20010525 (60)
DT      Utility
FS      GRANTED
LN.CNT 25550
INCL    INCLM: 514/012.000
        INCLS: 530/350.000; 536/023.500; 435/023.000
NCL     NCLM:  514/012.000; 435/006.000
        NCLS:  435/023.000; 530/350.000; 536/023.500; 435/007.900; 435/069.100;
               435/183.000; 435/320.100; 435/325.000; 536/023.200; 800/003.000
IC      [7]
        ICM    C12Q001-37
        ICS    C07H021-04; C07K014-00; A61K038-00
        IPCI   C12Q0001-68 [ICM,7]; G01N0033-53 [ICS,7]; G01N0033-542 [ICS,7];
```

G01N0033-536 [ICS,7,C*]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*]; C12N0009-00 [ICS,7]; C12P0021-02 [ICS,7]; C12N0005-06 [ICS,7]
IPCI-2 C12Q0001-37 [ICM,7]; C07H0021-04 [ICS,7]; C07H0021-00 [ICS,7,C*]; C07K0014-00 [ICS,7]; A61K0038-00 [ICS,7]
IPCR A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0048-00 [N,C*]; A61K0048-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-47 [I,A]
EXF 435/23; 530/350; 536/23.5; 514/12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 26 OF 28 USPAT2 on STN
AN 2003:99573 USPAT2
TI WISP polypeptides and nucleic acids encoding same
IN Levine, Arnold J., New York, NY, UNITED STATES
Pennica, Diane, Burlingame, CA, UNITED STATES
PA Genentech, Inc., South San Francisco, CA, UNITED STATES (U.S. corporation)
PI US 7101850 B2 20060905
AI US 2002-112267 20020327 (10)
RLI Division of Ser. No. US 1998-182145, filed on 29 Oct 1998, Pat. No. US 6387657
PRAI US 1998-81695P 19980414 (60)
US 1998-73612P 19980204 (60)
US 1997-63704P 19971029 (60)
DT Utility
FS GRANTED
LN.CNT 9667
INCL INCLM: 514/012.000
INCLS: 530/350.000
NCL NCLM: 514/012.000; 435/069.100
NCLS: 530/350.000; 435/183.000; 435/320.100; 435/325.000; 536/023.500
IC IPCI C07H0021-04 [ICM,7]; C07H0021-00 [ICM,7,C*]; C12N0009-00 [ICS,7]; C12P0021-02 [ICS,7]; C12N0005-06 [ICS,7]
IPCI-2 A61K0038-00 [I,A]
IPCR C07H0021-00 [I,C*]; C07H0021-04 [I,A]; C12N0001-16 [I,C*]; C12N0001-16 [I,A]; C12N0001-21 [I,C*]; C12N0001-21 [I,A]; C12N0005-06 [I,C*]; C12N0005-06 [I,A]; C12N0005-16 [I,C*]; C12N0005-16 [I,A]; C12N0009-00 [I,C*]; C12N0009-00 [I,A]; C12N0015-12 [I,C*]; C12N0015-12 [I,A]; C12N0015-63 [I,C*]; C12N0015-63 [I,A]; C12P0021-02 [I,C*]; C12P0021-02 [I,A]
EXF 424/198.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 27 OF 28 USPAT2 on STN
AN 2003:37603 USPAT2
TI Isolated human vCOL16A1 polypeptide and fragments thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA Serono Genetics Institute S.A., Evry, FRANCE (non-U.S. corporation)
PI US 7074901 B2 20060711
AI US 2001-924340 20010806 (9)
PRAI US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS GRANTED
LN.CNT 25381
INCL INCLM: 530/356.000
INCLS: 530/324.000
NCL NCLM: 530/356.000; 435/069.100
NCLS: 530/324.000; 435/006.000; 435/183.000; 435/320.100; 435/325.000;

```
              530/350.000; 536/023.200
IC     IPCI   C12P0021-02 [ICM,7]; C12Q0001-68 [ICS,7]; C07H0021-04 [ICS,7];
              C07H0021-00 [ICS,7,C*]; C12N0009-00 [ICS,7]; C12N0005-06 [ICS,7]
       IPCI-2 C07K0014-78 [I,A]; C07K0014-435 [I,C*]
       IPCR   A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0048-00 [N,C*];
              A61K0048-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-47 [I,A];
              C07K0014-435 [I,C]; C07K0014-78 [I,A]
EXF    530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9   ANSWER 28 OF 28  USPAT2 on STN
AN     2003:37516  USPAT2
TI     Serine carboxypeptidase hx (SCPhx) and compositions thereof
IN     Bejanin, Stephane, Paris, FRANCE
       Tanaka, Hiroaki, Antony, FRANCE
PA     Serono Genetics Institute SA, FRANCE (non-U.S. corporation)
PI     US 7074571          B2  20060711
AI     US 2001-992600          20011113 (9)
RLI    Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI   WO 2001-IB1715      20010806
       US 2001-305456P     20010713 (60)
       US 2001-302277P     20010629 (60)
       US 2001-298698P     20010615 (60)
       US 2001-293574P     20010525 (60)
DT     Utility
FS     GRANTED
LN.CNT 25479
INCL   INCLM: 435/007.100
       INCLS: 435/069.100; 435/071.100; 435/183.000; 435/212.000; 435/219.000;
              530/350.000; 530/412.000; 530/413.000
NCL    NCLM:  435/007.100; 435/006.000
       NCLS:  435/069.100; 435/071.100; 435/183.000; 435/212.000; 435/219.000;
              530/350.000; 530/412.000; 530/413.000; 435/320.100; 435/325.000;
              536/023.200; 800/008.000
IC     IPCI   C12Q0001-68 [ICM,7]; A01K0067-00 [ICS,7]; C07H0021-04 [ICS,7];
              C07H0021-00 [ICS,7,C*]; C12N0009-00 [ICS,7]; C12P0021-02 [ICS,7];
              C12N0005-06 [ICS,7]
       IPCI-2 G01N0033-53 [I,A]; C07K0014-435 [I,A]; C12N0009-12 [I,A]
       IPCR   A61K0038-00 [N,C*]; A61K0038-00 [N,A]; A61K0048-00 [N,C*];
              A61K0048-00 [N,A]; C07K0014-435 [I,C*]; C07K0014-47 [I,A];
              G01N0033-53 [I,A]; C07K0014-435 [I,C]; C07K0014-435 [I,A];
              C12N0009-12 [I,C]; C12N0009-12 [I,A]; G01N0033-53 [I,C]
EXF    530/350; 530/323; 530/324; 530/325; 530/326; 530/327; 530/328; 530/329;
       530/330; 435/183; 435/212; 435/219
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> s osteoblast produc? and lactoperoxidase
  11 FILES SEARCHED...
L10          1 OSTEOBLAST PRODUC? AND LACTOPEROXIDASE

=> d l10 1

L10  ANSWER 1 OF 1  USPATFULL on STN
AN     2007:23595  USPATFULL
TI     Full-length cDNA
IN     Isogai, Takao, Ibaraki, JAPAN
       Sugiyama, Tomoyasu, Tokyo, JAPAN
       Otsuki, Tetsuji, Tokyo, JAPAN
       Wakamatsu, Al, Chiba, JAPAN
       Sato, Hiroyuki, Osaka, JAPAN
       Ishii, Shizuko, Hokkaido, JAPAN
```

```
       Yamamoto, Junichi, Chiba, JAPAN
       Isono, Yuko, Chiba, JAPAN
       Nagai, Keiichi, Tokyo, JAPAN
       Irie, Ryotaro, Saitama, JAPAN
PA     RESEARCH ASSOCIATION FOR BIOTECHNOLOGY (non-U.S. corporation)
PI     US 20070020637      A1  20070125
AI     US 2004-760320      A1  20040121 (10)
PRAI   JP 2003-102206      20030121
       JP 2003-131392      20030509
       US 2003-476227P     20030606 (60)
       US 2003-447287P     20030214 (60)
DT     Utility
FS     APPLICATION
LN.CNT 117230
INCL   INCLM: 435/006.000
       INCLS: 536/023.100
NCL    NCLM:  435/006.000
       NCLS:  536/023.100
IC     IPCI   C12Q0001-68 [I,A]; C07H0021-04 [I,A]; C07H0021-00 [I,C*]
       IPCR   C12Q0001-68 [I,C]; C12Q0001-68 [I,A]; C07H0021-00 [I,C];
              C07H0021-04 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> d l10 1 ab

L10  ANSWER 1 OF 1  USPATFULL on STN
AB     Novel full-length cDNAs are provided. 2,495 cDNA derived from human have
       been isolated. The full-length nucleotide sequences of the cDNA and
       amino acid sequences encoded by the nucleotide sequences have been
       determined. Because the cDNA of the present invention are full-length
       and contain the translation start site, they provide information useful
       for analyzing the functions of the polypeptide.


=> file uspatfull
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      79.77      82.58

FILE 'USPATFULL' ENTERED AT 21:01:45 ON 20 JUN 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 19 Jun 2008 (20080619/PD)
FILE LAST UPDATED: 19 Jun 2008 (20080619/ED)
HIGHEST GRANTED PATENT NUMBER: US7389542
HIGHEST APPLICATION PUBLICATION NUMBER: US20080148460
CA INDEXING IS CURRENT THROUGH 19 Jun 2008 (20080619/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 19 Jun 2008 (20080619/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2008
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2008


=> s lactoperoxidase in food
          2700 LACTOPEROXIDASE
        244599 FOOD
L11          0 LACTOPEROXIDASE IN FOOD
                 (LACTOPEROXIDASE(1W)FOOD)

=> s food containing lactoperoxidase
        244599 FOOD
       2059046 CONTAINING
```

```
          2700 LACTOPEROXIDASE
L12          0 FOOD CONTAINING LACTOPEROXIDASE
                 (FOOD(W)CONTAINING(W)LACTOPEROXIDASE)

=> s food and lactoperoxidase
        244599 FOOD
          2700 LACTOPEROXIDASE
L13        707 FOOD AND LACTOPEROXIDASE

=> s l13 and (drink or feed)
         28894 DRINK
        573082 FEED
L14        191 L13 AND (DRINK OR FEED)

=> s l14 and contain?(p)lactoperoxidase
       3069451 CONTAIN?
          2700 LACTOPEROXIDASE
           831 CONTAIN?(P)LACTOPEROXIDASE
L15         88 L14 AND CONTAIN?(P)LACTOPEROXIDASE

=> s l15 and bone
        137746 BONE
L16         14 L15 AND BONE

=> d l16 1-14

L16  ANSWER 1 OF 14  USPATFULL on STN
AN     2008:158939  USPATFULL
TI     Compositions and methods for treatment of cancer
IN     de Sauvage, Fred, Foster City, CA, UNITED STATES
       Goddard, Audrey, San Francisco, CA, UNITED STATES
       Gurney, Austin L., Belmont, CA, UNITED STATES
       Hongo, Jo-Anne, Redwood City, CA, UNITED STATES
       Smith, Victoria, Burlingame, CA, UNITED STATES
PA     Genentech, Inc. (U.S. corporation)
PI     US 20080138345      A1  20080612
AI     US 2005-120399      A1  20050502 (11)
RLI    Continuation of Ser. No. US 2001-769087, filed on 24 Jan 2001, ABANDONED
PRAI   US 2000-177951P     20000125 (60)
       US 2000-195761P     20000410 (60)
DT     Utility
FS     APPLICATION
LN.CNT 5318
INCL   INCLM: 424/139.100
       INCLS: 530/387.900; 435/331.000; 435/072.300; 424/178.100; 530/387.300;
              435/252.800; 435/255.100
NCL    NCLM:  424/139.100
       NCLS:  530/387.900; 435/331.000; 435/072.300; 424/178.100; 530/387.300;
              435/252.800; 435/255.100
IC     IPCI   A61K0039-395 [I,A]; C07K0016-00 [I,A]; C12N0005-00 [I,A];
              C12N0005-06 [I,A]; C12N0001-16 [I,A]; C12N0001-20 [I,A];
              A61P0035-04 [I,A]; A61P0035-00 [I,C*]; G01N0033-574 [I,A]

L16  ANSWER 2 OF 14  USPATFULL on STN
AN     2008:50792  USPATFULL
TI     MILK PROTEIN ISOLATE AND PROCESS FOR ITS PREPARATION
IN     Souppe, Jerome, Rennes, FRANCE
PA     Compagnie Laitiere Europeene (non-U.S. corporation)
PI     US 20080044544      A1  20080221
AI     US 2007-757485      A1  20070604 (11)
RLI    Continuation of Ser. No. US 2005-519131, filed on 4 Aug 2005, GRANTED,
       Pat. No. US 7247331 A 371 of International Ser. No. WO 2003-FR2015,
```

filed on 30 Jun 2003
PRAI FR 2002-8234 20020702
DT Utility
FS APPLICATION
LN.CNT 605
INCL INCLM: 426/580.000
NCL NCLM: 426/580.000
IC IPCI A23C0009-00 [I,A]
IPCR A23C0009-00 [I,C]; A23C0009-00 [I,A]; A23C0009-146 [I,A];
A23J0001-00 [I,C*]; A23J0001-20 [I,A]; A23L0001-305 [I,C*];
A23L0001-305 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A];
A61K0038-40 [I,C*]; A61K0038-40 [I,A]; A61P0019-00 [I,C*];
A61P0019-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 3 OF 14 USPATFULL on STN
AN 2007:302272 USPATFULL
TI COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
IN de Sauvage, Frederic, Foster City, CA, UNITED STATES
Goddard, Audrey, San Francisco, CA, UNITED STATES
Gurney, Austin L., Belmont, CA, UNITED STATES
Hongo, Jo-Anne S., Redwood City, CA, UNITED STATES
Smith, Victoria, Burlingame, CA, UNITED STATES
PA Genentech, Inc., South San Francisco, CA, UNITED STATES (U.S.
corporation)
PI US 20070264267 A1 20071115
AI US 2006-538881 A1 20061005 (11)
RLI Continuation of Ser. No. US 2002-182033, filed on 24 Oct 2002, PENDING A
371 of International Ser. No. WO 2001-US2622, filed on 25 Jan 2001
PRAI US 2000-177951P 20000125 (60)
US 2000-195761P 20000410 (60)
DT Utility
FS APPLICATION
LN.CNT 5472
INCL INCLM: 424/183.100
INCLS: 435/252.330; 435/254.200; 435/346.000; 435/348.000; 435/358.000;
435/006.000; 435/007.920; 530/324.000; 530/391.700; 536/023.100
NCL NCLM: 424/183.100
NCLS: 435/006.000; 435/007.920; 435/252.330; 435/254.200; 435/346.000;
435/348.000; 435/358.000; 530/324.000; 530/391.700; 536/023.100
IC IPCI A61K0039-395 [I,A]; A61P0035-00 [I,A]; C07H0021-04 [I,A];
C07H0021-00 [I,C*]; C07K0014-00 [I,A]; C07K0016-00 [I,A];
C12N0001-19 [I,A]; C12N0001-21 [I,A]; C12N0005-10 [I,A];
C12N0005-12 [I,A]; C12Q0001-68 [I,A]; G01N0033-574 [I,A]
IPCR A61K0039-395 [I,C]; A61K0039-395 [I,A]; A61P0035-00 [I,C];
A61P0035-00 [I,A]; C07H0021-00 [I,C]; C07H0021-04 [I,A];
C07K0014-00 [I,C]; C07K0014-00 [I,A]; C07K0014-435 [I,C*];
C07K0014-47 [I,A]; C07K0016-00 [I,C]; C07K0016-00 [I,A];
C07K0016-18 [I,C*]; C07K0016-30 [I,A]; C12N0001-19 [I,C];
C12N0001-19 [I,A]; C12N0001-21 [I,C]; C12N0001-21 [I,A];
C12N0005-10 [I,C]; C12N0005-10 [I,A]; C12N0005-12 [I,C];
C12N0005-12 [I,A]; C12Q0001-68 [I,C]; C12Q0001-68 [I,A];
G01N0033-574 [I,C]; G01N0033-574 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 4 OF 14 USPATFULL on STN
AN 2007:290246 USPATFULL
TI Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof
IN Naidu, A. Satyanarayan, Diamond Bar, CA, UNITED STATES
Naidu, A.G. Tezus, Diamond Bar, CA, UNITED STATES
Naidu, A.G. Sreus, Diamond Bar, CA, UNITED STATES
PI US 20070253941 A1 20071101

AI US 2006-482653 A1 20060707 (11)
PRAI US 2006-795871P 20060428 (60)
DT Utility
FS APPLICATION
LN.CNT 2445
INCL INCLM: 424/094.100
  INCLS: 514 6; 514/690.000
NCL NCLM: 424/094.100
  NCLS: 514/006.000; 514/690.000
IC IPCI A61K0038-43 [I,A]; A61K0038-40 [I,A]; A61K0031-12 [I,A]
  IPCR A61K0038-43 [I,C]; A61K0038-43 [I,A]; A61K0031-12 [I,C];
    A61K0031-12 [I,A]; A61K0038-40 [I,C]; A61K0038-40 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 5 OF 14 USPATFULL on STN
AN 2006:267664 USPATFULL
TI Osteogenesis promoter
IN Motouri, Mutsumi, Saitama, JAPAN
  Matsuyama, Hiroaki, Saitama, JAPAN
  Morita, Yoshikazu, Saitami, JAPAN
  Serizawa, Atsushi, Saitama, JAPAN
  Kawakami, Hiroshi, Saitama, JAPAN
PI US 20060228345 A1 20061012
AI US 2004-566711 A1 20040813 (10)
  WO 2004-JP11689 20040813
    20060315 PCT 371 date
PRAI JP 2003-293829 20030815
DT Utility
FS APPLICATION
LN.CNT 420
INCL INCLM: 424/094.400
  INCLS: 424/439.000
NCL NCLM: 424/094.400
  NCLS: 424/439.000
IC IPCI A61K0038-44 [I,A]; A61K0038-43 [I,C*]; A61K0047-00 [I,A]
  IPCR A61K0038-43 [I,C]; A61K0038-44 [I,A]; A23K0001-165 [I,C*];
    A23K0001-165 [I,A]; A23L0001-30 [I,C*]; A23L0001-30 [I,A];
    A23L0001-305 [I,C*]; A23L0001-305 [I,A]; A61K0035-20 [I,C*];
    A61K0035-20 [I,A]; A61K0038-00 [I,C*]; A61K0038-00 [I,A];
    A61K0047-00 [I,C]; A61K0047-00 [I,A]; A61P0019-00 [I,C*];
    A61P0019-00 [I,A]; A61P0019-08 [I,A]; A61P0019-10 [I,A];
    A61P0043-00 [I,C*]; A61P0043-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 6 OF 14 USPATFULL on STN
AN 2006:46555 USPATFULL
TI Milk protein isolate and method for preparing same
IN Souppe, Jerome, Rennes, FRANCE
PI US 20060040025 A1 20060223
  US 7247331 B2 20070724
AI US 2003-519131 A1 20030630 (10)
  WO 2003-FR2015 20030630
    20050804 PCT 371 date
PRAI FR 2002-8234 20020702
DT Utility
FS APPLICATION
LN.CNT 707
INCL INCLM: 426/490.000
  INCLS: 426/580.000
NCL NCLM: 426/491.000; 426/490.000
  NCLS: 426/271.000; 426/580.000; 426/587.000; 426/588.000; 426/590.000;
    514/775.000; 530/416.000

IC IPCI C12G0003-08 [I,A]; C12G0003-00 [I,C*]
IPCI-2 A23C0001-00 [I,A]; A23J0001-20 [I,A]; A23J0001-00 [I,C*]; A23L0002-38 [I,A]; A61K0047-00 [I,A]; C07K0001-18 [I,A]; C07K0001-00 [I,C*]
IPCR A23C0001-00 [I,C]; A23C0001-00 [I,A]; A23C0009-00 [I,C*]; A23C0009-146 [I,A]; A23J0001-00 [I,C]; A23J0001-20 [I,A]; A23L0001-305 [I,C*]; A23L0001-305 [I,A]; A23L0002-38 [I,C]; A23L0002-38 [I,A]; A61K0038-17 [I,C*]; A61K0038-17 [I,A]; A61K0038-40 [I,C*]; A61K0038-40 [I,A]; A61K0047-00 [I,C]; A61K0047-00 [I,A]; A61P0019-00 [I,C*]; A61P0019-00 [I,A]; C07K0001-00 [I,C]; C07K0001-18 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 7 OF 14 USPATFULL on STN
AN 2005:298585 USPATFULL
TI Medicinal products incorporating bound organosulfur groups
IN Ott, David M., Oakland, CA, UNITED STATES
PI US 20050260250 A1 20051124
AI US 2005-137747 A1 20050524 (11)
PRAI US 2004-574374P 20040524 (60)
DT Utility
FS APPLICATION
LN.CNT 3695
INCL INCLM: 424/439.000
INCLS: 514/012.000; 424/754.000
NCL NCLM: 424/439.000
NCLS: 424/754.000; 514/012.000
IC [7]
ICM A61K035-78
ICS A61K038-16; A61K047-00
IPCI A61K0035-78 [ICM,7]; A61K0038-16 [ICS,7]; A61K0047-00 [ICS,7]
IPCR A23L0001-221 [I,C*]; A23L0001-221 [I,A]; A23L0001-30 [I,C*]; A23L0001-30 [I,A]; A23L0001-305 [I,C*]; A23L0001-305 [I,A]; A61K0036-88 [I,C*]; A61K0036-8962 [I,A]; A61K0038-16 [I,C*]; A61K0038-16 [I,A]; A61K0047-00 [I,C*]; A61K0047-00 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 8 OF 14 USPATFULL on STN
AN 2005:98544 USPATFULL
TI Filters for preventing or reducing tobacco smoke-associated injury in the aerodigestive tract of a subject
IN Reznick, Abraham Z., Nofit, ISRAEL
Nagler, Rafael M., Timrat, ISRAEL
Klein, Ifat, Doar Na Galil Elion, ISRAEL
PI US 20050084459 A1 20050421
AI US 2004-931213 A1 20040901 (10)
RLI Division of Ser. No. US 2001-987688, filed on 15 Nov 2001, GRANTED, Pat. No. US 6789546
PRAI US 2001-304402P 20010712 (60)
US 2001-300443P 20010626 (60)
DT Utility
FS APPLICATION
LN.CNT 1648
INCL INCLM: 424/048.000
INCLS: 424/049.000; 424/058.000
NCL NCLM: 424/048.000
NCLS: 424/049.000; 424/058.000
IC [7]
ICM A61K009-68
ICS A61K007-16; A61K007-26
IPCI A61K0009-68 [ICM,7]; A61K0007-16 [ICS,7]; A61K0007-26 [ICS,7]
IPCR A61K0031-7135 [I,C*]; A61K0031-714 [I,A]

L16 ANSWER 9 OF 14 USPATFULL on STN
AN   2004:146090 USPATFULL
TI   Expression of human milk proteins in transgenic plants
IN   Huang, Ning, Davis, CA, UNITED STATES
       Rodriguez, Raymond L., Davis, CA, UNITED STATES
       Hagie, Frank E., Sacramento, CA, UNITED STATES
PA   Ventria Bioscience (U.S. corporation)
PI   US 20040111766   A1 20040610
AI   US 2003-639835   A1 20030812 (10)
RLI   Continuation-in-part of Ser. No. US 2002-77381, filed on 14 Feb 2002,
       PENDING Continuation-in-part of Ser. No. US 2001-847232, filed on 2 May
       2001, PENDING
PRAI   US 2001-269199P   20010214 (60)
       US 2001-266929P   20010206 (60)
       US 2000-201182P   20000502 (60)
DT   Utility
FS   APPLICATION
LN.CNT 5337
INCL   INCLM: 800/288.000
       INCLS: 800/320.200; 800/320.300
NCL   NCLM: 800/288.000
       NCLS: 800/320.200; 800/320.300
IC   [7]
       ICM   A01H001-00
       ICS   C12N015-82; A01H005-00
       IPCI   A01H0001-00 [ICM,7]; C12N0015-82 [ICS,7]; A01H0005-00 [ICS,7]
       IPCR   A23K0001-14 [I,C*]; A23K0001-14 [I,A]; A23K0001-16 [I,C*];
              A23K0001-16 [I,A]; A23L0001-10 [I,C*]; A23L0001-10 [I,A];
              A23L0001-185 [I,C*]; A23L0001-185 [I,A]; A23L0001-30 [I,C*];
              A23L0001-30 [I,A]; A23L0001-305 [I,C*]; A23L0001-305 [I,A];
              C07K0014-415 [I,C*]; C07K0014-415 [I,A]; C07K0014-435 [I,C*];
              C07K0014-485 [I,A]; C07K0014-65 [I,A]; C07K0014-79 [I,A];
              C07K0014-81 [I,C*]; C07K0014-81 [I,A]; C12N0009-08 [I,C*];
              C12N0009-08 [I,A]; C12N0009-36 [I,C*]; C12N0009-36 [I,A];
              C12N0015-82 [I,C*]; C12N0015-82 [I,A]; G01N0033-574 [I,C*];
              G01N0033-574 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 10 OF 14 USPATFULL on STN
AN   2003:306025 USPATFULL
TI   Compositions and methods for treatment of cancer
IN   Sauvage, Frederic de, Foster City, CA, UNITED STATES
       Goddard, Audrey, San Francisco, CA, UNITED STATES
       Gurney, Austin L., Belmont, CA, UNITED STATES
       Hongo, Jo-Anne S., Redwood City, CA, UNITED STATES
PI   US 20030215457   A1 20031120
       US 7285382   B2 20071023
AI   US 2002-182033   A1 20021024 (10)
       WO 2001-US2622   20010125
DT   Utility
FS   APPLICATION
LN.CNT 5446
INCL   INCLM: 424/185.100
       INCLS: 435/069.300; 435/320.100; 435/325.000; 530/350.000; 530/388.800;
              435/007.230
NCL   NCLM: 435/005.000; 424/185.100
       NCLS: 435/007.230; 435/069.300; 435/320.100; 435/325.000; 530/350.000;
              530/388.800
IC   [7]
       ICM   G01N033-574
       ICS   C07K014-47; C12P021-02; C12N005-06; C07K016-18

IPCI G01N0033-574 [ICM,7]; C07K0014-47 [ICS,7]; C07K0014-435 [ICS,7,C*]; C12P0021-02 [ICS,7]; C12N0005-06 [ICS,7]; C07K0016-18 [ICS,7]
IPCI-2 C12Q0001-70 [I,A]
IPCR C12Q0001-70 [I,C]; C12Q0001-70 [I,A]; C07K0014-435 [I,C*]; C07K0014-47 [I,A]; C07K0016-18 [I,C*]; C07K0016-30 [I,A]; G01N0033-574 [I,C*]; G01N0033-574 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 11 OF 14 USPATFULL on STN
AN 2003:172818 USPATFULL
TI Therapeutic uses of milk mineral fortified food products
IN Bastian, Eric Douglas, Twin Falls, ID, UNITED STATES
Ward, Loren Spencer, Twin Falls, ID, UNITED STATES
PA Glanbia Foods, Inc., Twin Falls, ID, UNITED STATES (U.S. corporation)
PI US 20030118662 A1 20030626
AI US 2001-2011 A1 20011205 (10)
DT Utility
FS APPLICATION
LN.CNT 444
INCL INCLM: 424/535.000
NCL NCLM: 424/535.000
IC [7]
ICM A61K035-20
IPCI A61K0035-20 [ICM,7]
IPCR A21D0002-00 [I,C*]; A21D0002-02 [I,A]; A23C0009-13 [I,C*]; A23C0009-13 [I,A]; A23C0009-133 [I,A]; A23G0003-00 [I,C*]; A23G0003-00 [I,A]; A23G0003-34 [I,C*]; A23G0003-36 [I,A]; A23G0003-46 [I,A]; A23L0001-304 [I,C*]; A23L0001-304 [I,A]; A23L0002-02 [I,C*]; A23L0002-02 [I,A]; A23L0002-52 [I,C*]; A23L0002-52 [I,A]; A61K0035-20 [I,C*]; A61K0035-20 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 12 OF 14 USPATFULL on STN
AN 2003:95803 USPATFULL
TI Periodontal disease preventive and ameliorative agent
IN Takada, Yukihiro, Kawagoe, JAPAN
Aoe, Seiichirou, Sayama, JAPAN
Serizawa, Atsusi, Kawagoe, JAPAN
Suguri, Toshiaki, Tokyo, JAPAN
Dousako, Shunichi, Urawa, JAPAN
PA Snow Brand Milk Products Co., Ltd., Hokkai-do, JAPAN (non-U.S. corporation)
PI US 6544498 B1 20030408
WO 9956762 19991111
AI US 2000-446279 20000320 (9)
WO 1999-JP2223 19990427
PRAI JP 1998-134243 19980430
DT Utility
FS GRANTED
LN.CNT 245
INCL INCLM: 424/049.000
INCLS: 514/012.000; 514/016.000; 514/021.000; 514/900.000; 514/901.000
NCL NCLM: 424/049.000
NCLS: 514/012.000; 514/016.000; 514/021.000; 514/900.000; 514/901.000
IC [7]
ICM A61K007-16
ICS A61K038-00
IPCI A61K0007-16 [ICM,7]; A61K0038-00 [ICS,7]
IPCR A61K0008-00 [I,C*]; A61K0008-00 [I,A]; A23G0004-00 [I,C*]; A23G0004-00 [I,A]; A23J0003-00 [I,C*]; A23J0003-08 [I,A]; A23L0001-305 [I,C*]; A23L0001-305 [I,A]; A61K0008-30 [I,C*];

A61K0008-64 [I,A]; A61K0035-20 [I,C*]; A61K0035-20 [I,A];
A61K0038-00 [I,C*]; A61K0038-00 [I,A]; A61K0038-01 [I,C*];
A61K0038-01 [I,A]; A61K0038-02 [I,C*]; A61K0038-02 [I,A];
A61K0038-17 [I,C*]; A61K0038-17 [I,A]; A61P0001-00 [I,C*];
A61P0001-02 [I,A]; A61Q0011-00 [I,C*]; A61Q0011-00 [I,A];
A23G0004-06 [I,C*]; A23G0004-12 [I,A]; A23G0004-14 [I,A];
A23G0004-16 [I,A]
EXF 514/12; 514/16; 514/21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 13 OF 14 USPATFULL on STN
AN 2003:80313 USPATFULL
TI Feed additive compositions and methods
IN Huang, Ning, Davis, CA, UNITED STATES
Rodriguez, Raymond L., Davis, CA, UNITED STATES
Hagie, Frank E., Sacramento, CA, UNITED STATES
PI US 20030056244 A1 20030320
AI US 2002-76816 A1 20020214 (10)
RLI Continuation-in-part of Ser. No. US 2001-847232, filed on 2 May 2001, PENDING
PRAI WO 2001-US14234 20011108
US 2001-269188P 20010214 (60)
US 2001-266929P 20010206 (60)
US 2000-201182P 20000502 (60)
DT Utility
FS APPLICATION
LN.CNT 5847
INCL INCLM: 800/278.000
INCLS: 424/442.000; 426/053.000
NCL NCLM: 800/278.000
NCLS: 424/442.000; 426/053.000
IC [7]
ICM A23K001-165
ICS A23K001-17
IPCI A23K0001-165 [ICM,7]; A23K0001-17 [ICS,7]
IPCR A23K0001-14 [I,C*]; A23K0001-14 [I,A]; A23K0001-16 [I,C*];
A23K0001-16 [I,A]; A23L0001-185 [I,C*]; A23L0001-185 [I,A];
A23L0001-30 [I,C*]; A23L0001-30 [I,A]; A23L0001-305 [I,C*];
A23L0001-305 [I,A]; C07K0014-415 [I,C*]; C07K0014-415 [I,A];
C07K0014-435 [I,C*]; C07K0014-485 [I,A]; C07K0014-65 [I,A];
C07K0014-79 [I,A]; C07K0014-81 [I,C*]; C07K0014-81 [I,A];
C12N0009-08 [I,C*]; C12N0009-08 [I,A]; C12N0009-36 [I,C*];
C12N0009-36 [I,A]; C12N0015-82 [I,C*]; C12N0015-82 [I,A];
G01N0033-574 [I,C*]; G01N0033-574 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L16 ANSWER 14 OF 14 USPATFULL on STN
AN 1999:88838 USPATFULL
TI Bone reinforcing agent and foods and drinks product containing the same
IN Kato, Ken, 11-3, Arajuku-cho 5-chome, Kawagoe, Japan
Matsuyama, Hiroaki, 11-3, Arajuku-cho 5-chome, Kawagoe, Japan
Takada, Yukihiro, 62-22, Kozutsumi, Kawagoe, Japan
Uchida, Toshiaki, 11-3, Arajuku-cho 5-chome, Kawagoe, Japan
Aoe, Seiichiro, 8-9-406 Shinsayama 2-chome, Satana, Japan
PI US 5932259 19990803
AI US 1995-532399 19950922 (8)
PRAI JP 1994-261609 19940930
JP 1995-207509 19950721
DT Utility
FS Granted
LN.CNT 459

```
INCL   INCLM: 426/042.000
       INCLS: 426/041.000; 426/656.000; 426/657.000; 426/800.000
NCL    NCLM:  426/042.000
       NCLS:  426/041.000; 426/656.000; 426/657.000; 426/800.000
IC     [6]
       ICM    A23C009-12
       IPCI   A23C0009-12 [ICM,6]
       IPCR   A23L0002-52 [I,C*]; A23L0002-52 [I,A]; A23J0003-00 [I,C*];
              A23J0003-08 [I,A]; A23L0001-305 [I,C*]; A23L0001-305 [I,A];
              A61K0035-20 [I,C*]; A61K0035-20 [I,A]; A61K0038-00 [I,C*];
              A61K0038-00 [I,A]; A61K0038-01 [I,C*]; A61K0038-01 [I,A];
              A61K0038-17 [I,C*]; A61K0038-17 [I,A]; A61P0019-00 [I,C*];
              A61P0019-08 [I,A]; A61P0019-10 [I,A]; A61P0043-00 [I,C*];
              A61P0043-00 [I,A]; C12N0009-48 [I,C*]; C12N0009-48 [I,A];
              C12N0009-76 [I,C*]; C12N0009-76 [I,A]; C12N0009-94 [I,C*];
              C12N0009-94 [I,A]; C12P0021-06 [I,C*]; C12P0021-06 [I,A]
EXF    426/41; 426/42; 426/34; 426/656; 426/580; 426/55; 426/56; 426/657;
       426/800; 426/801; 426/810; 435/192
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> d l16 ab

L16  ANSWER 1 OF 14  USPATFULL on STN
AB     The present invention concerns compositions and methods for the
       treatment of disorders characterized by the overexpression of an LIV-1.
       More specifically, the compositions include DNA and amino acid sequences
       of an LIV-1, antibodies to an LIV-1, and methods for the treatment of a
       mammal susceptible to or diagnosed with cancer wherein an LIV-1 is
       overexpressed.


=> d l16 14 ab

L16  ANSWER 14 OF 14  USPATFULL on STN
AB     A bone reinforcing agent comprising a basic protein fraction
       or a basic peptide fraction derived from milk as an effective component
       is described. The basic protein fraction is obtained by passing milk or
       a raw material derived from milk over a cation exchange resin and
       eluting the adhered fraction. The basic peptide fraction is obtained by
       hydrolyzing the basic protein fraction with a protease. The basic
       protein fraction and basic peptide fraction of the present invention
       promote the growth of osteoclasts and suppress the resorption of
       osteoclasts, and thereby strengthening bone when administered
       orally. The invention is useful for treating or preventing bone
       diseases such as osteoporosis.


=> d l16 14 kwic

L16  ANSWER 14 OF 14  USPATFULL on STN
TI     Bone reinforcing agent and foods and drinks product containing
       the same
AB     A bone reinforcing agent comprising a basic protein fraction
       or a basic peptide fraction derived from milk as an effective component
       is.  .  .  peptide fraction of the present invention promote the growth
       of osteoclasts and suppress the resorption of osteoclasts, and thereby
       strengthening bone when administered orally. The invention is
       useful for treating or preventing bone diseases such as
       osteoporosis.
SUMM   The present invention relates to a bone reinforcing agent and
       food and drink products containing the same,
```

exhibiting a bone reinforcing activity. Because the bone reinforcing agent and the food and drink products containing the same of the present invention exhibit the effects of promoting the growth of osteoblasts and suppressing bone resorption by osteoblasts, they are useful in treating or preventing various bone diseases such as osteoporosis, bone fractures, rheumatism, and arthritis.

SUMM In recent years, the incidence of bone diseases such as osteoporosis, bone fractures, lumbago, and the like, have increased along with the progressive increase in the elderly population. These diseases are caused by insufficient calcium intake, decreased calcium absorption hormonal imbalance postmenopause, and the like. Increasing the peak bone mass, or the total amount of bone in the body, is considered to be effective in preventing bone diseases such as osteoporosis, bone fractures, lumbago, and the like in aged people. Increasing the peak bone mass is equivalent to strengthening the bone. Controlling bone resorption is also considered to be effective in preventing osteoporosis. Bone synthesis is characterized by a repeated balanced formation-resorption cycle which is called remodeling. Hormonal imbalance postmenopause causes bone resorption to predominate over bone formation, resulting in osteoporosis. Accordingly, bones are reinforced by controlling bone resorption and maintaining bone mass at a certain level.

SUMM . . . calcium salts (e.g. calcium carbonate, calcium lactate or calcium phosphate), milk or whey calcium, and natural calcium agents (e.g. cattle bone meal or egg shell), and the like, are used to strengthen the bones. These agents are individually administered or added. . . . excreted without being absorbed by the body. Even if absorbed, calcium may not necessarily be utilized for the improvement of bone metabolism or for the reinforcement of bones because the affinity of calcium for bone differs according to the form of the calcium and types of other nutrients which are taken together with calcium. Vitamin. . . . may be accompanied by side effects such as ear noises, headache, and anorexia. Furthermore, the addition of these drugs to food or drink is currently infeasible due to safety, and cost considerations. Therefore, the development of a bone reinforcing agent, or a food or drink product containing a bone reinforcing agent, which can be orally administered over an extended period of time and which directly exhibits the bone growth promoting effect or the bone resorption suppressing effect, and is effective in the treatment or prevention of the osteoporosis, is desirable.

SUMM In view of the above-mentioned problems, the present inventors have undertaken extensive research into the substances contained in various raw food materials which exhibit a bone reinforcing effect. This research has resulted in the finding that a basic protein fraction derived from milk or basic peptide. . . . as pepsin or pancreatin, exhibit the effects of promoting growth of osteoblasts and suppressing resorption of osteoclasts, and can strengthen bone when administered orally. The inventors of the present invention have found that the basic protein fractions and the basic peptide fraction can be used as a bone reinforcing agent or as an effective component for bone reinforcing food and drinks. These findings have led to the present invention.

SUMM Accordingly, an object of the present invention is to provide a bone reinforcing agent and a food or drink product containing the same, exhibiting the effects of promoting growth of osteoblasts and suppressing resorption of osteoclasts, thereby strengthening bone without causing side effects.

SUMM The object of the present invention is to obtain a bone reinforcing agent or a food or drink product

containing the same which contains a basic protein fraction derived from milk or a basic peptide fraction obtained by. . .

SUMM Specifically, the present invention relates to a bone reinforcing agent which contains a basic protein fraction derived from milk or a basic peptide fraction obtained by hydrolyzing this. . .

SUMM The present invention further relates to a bone reinforcing food or drink product which contains the basic protein fraction or the basic peptide fraction, as an effective component.

DRWD FIG. 3 shows the osteoclast bone resorption suppressing activity of the basic protein fraction and the basic peptide fraction of the present invention in Test Example. . .

DETD . . . a basic peptide fraction obtained by hydrolyzing the basic protein fraction with a protease, as an effective component of a bone reinforcing agent or a food or drink containing the same. The basic protein fraction can be obtained from the milk of a mammal such as a cow,. . . peptide fraction can be obtained by hydrolyzing the basic protein fraction with a protease. These fractions act directly on the bone to exhibit a bone reinforcing effect and a bone resorption suppressing effect, and thereby strengthen the bone. As later described in detail in the Test Examples 1-4, the basic protein fraction derived from milk has the following. . .

DETD 3) The major proteins are lactoferrin and lactoperoxidase.

DETD The basic protein fraction or the basic peptide fraction, which is the effective component of the bone reinforcing agent of the present invention, may be administered as is or in suitable forms such as powder, granules, tablets,. . . or after it has been processed into suitable forms, into nutrients, drinks, or foods, to strengthen the bones by promoting bone formation or suppressing bone resorption. Because the milk-derived basic protein fraction and the basic peptide fraction of the present invention are comparatively stable with. . .

DETD . . . Tests using rats confirmed that the amount of the basic protein fraction or the basic peptide fraction for exhibiting the bone reinforcing effect is 0.1% by weight or more in feed. Accordingly, the bone reinforcing effect can be illicited by administering the basic protein fraction or the basic peptide fraction at a dose of 0.5 g/day or more to an adult, who generally takes 500 g/day on a dry basis of food and drink.

DETD Because the bone reinforcing agent and the food or drink containing the same of the present invention promote bone formation and suppress bone resorption, the bones are reinforced if they are administered. Accordingly, the bone reinforcing agent and the food or drink containing the same are useful for treating or preventing various bone diseases, such as osteoporosis, bone fractures, rheumatism, and arthritis and are particularly effective in treating or preventing osteoporosis. Further, it is possible to increase the peak bone mass in the growth period by administering the bone reinforcing agent or a food or drink containing the same of the present invention to infants and children.

DETD . . . in Example 1 was analyzed. The results are shown in Table 2. These results indicate that the basic protein fraction contains 40 wt. % or more of lactoferrin and 40 wt. % or more of lactoperoxidase.

DETD TABLE 2

	(wt. %)
Lactoferrin	42.5
Lactoperoxidase	45.6
Insulin-like growth factor-I	

	0.005
factor-I	
Others	11.895

DETD Femora were extirpated from rabbits (age: 10 days) and the soft tissues were removed. All the bone marrow cells containing osteoclasts, prepared by mechanically pulverizing the femora in a medium containing 5% FBS, were plated over a. . . with 10% of a solution prepared by diluting the liquid collected from the insides of each inverted gut sac threefold. Bone resorption pits created on the ivory were stained with hematoxylin and counted to determine the effect of suppressing osteoclast resorption. . .

DETD . . . which only the Ringer's solution was used as the external solution. These results confirmed that the effective component of the bone reinforcing agent of the present invention can pass through the gastrointestinal tract.

DETD The bone reinforcing effect of the basic protein fraction obtained in Example 2 was measured in experiments using animals.

DETD . . . 300 mg of calcium, 230 mg of phosphorous, and 50 mg of magnesium were added to each 100 g of food.

DETD After 4 weeks, both the femora and tibiae were extirpated. The breaking force of the femora was measured using a bone fracture properties measuring device (Rheometer Max RX-1600, trademark, manufactured by Aitekno Co. Ltd.). The tibiae were electrically demineralized and stained. . .

DETD A bone reinforcing drink of the composition shown in Table 5 was prepared.

DETD A paste with a composition shown in Table 6 was formed and baked to make a bone reinforcing biscuit.

DETD Tablets of bone reinforcing agent with a composition shown in Table 7 were prepared.

CLM What is claimed is:
1. A bone reinforcing agent comprising, as an effective component, a basic protein fraction derived from milk having an amino acid composition containing. . .

CLM What is claimed is:
2. The bone reinforcing agent according to claim 1, wherein the basic protein fraction derived from milk is obtained by contacting milk or. . .

CLM What is claimed is:
3. A bone reinforcing agent comprising, as an effective component, a basic peptide fraction having an average molecular weight of 4,000 Da or. . .

CLM What is claimed is:
4. The bone reinforcing agent according to claim 3, wherein the protease is selected from the group consisting of pepsin, trypsin, and chymotrypsin.
. . .

CLM What is claimed is:
5. The bone reinforcing agent according to claim 3, wherein the protease is pancreatin and at least one protease selected from the group. . .

CLM What is claimed is:
6. The bone reinforcing agent according to claim 1, which exhibits effects of promoting growth of osteoblasts and suppressing resorption of osteoclasts.

CLM What is claimed is:
7. A food or drink composition comprising the basic protein fraction derived from milk defined in claims 1 or 3.

```
=> d hist

     (FILE 'HOME' ENTERED AT 20:53:41 ON 20 JUN 2008)

     INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
     AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
     CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
     DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 20:53:49 ON 20 JUN 2008
               SEA LACTOPEROXIDASE AND OSTEO?
               ---------
                1   FILE AGRICOLA
                9   FILE BIOSIS
                1   FILE BIOTECHABS
                1   FILE BIOTECHDS
                2   FILE BIOTECHNO
                3   FILE CABA
               13   FILE CAPLUS
                1   FILE DGENE
                2   FILE DRUGU
               10   FILE EMBASE
                2   FILE ESBIOBASE
                3   FILE FROSTI
                3   FILE FSTA
                4   FILE IFIPAT
                2   FILE LIFESCI
                5   FILE MEDLINE
                1   FILE PASCAL
                2   FILE PROMT
                5   FILE SCISEARCH
                3   FILE TOXCENTER
              587   FILE USPATFULL
               97   FILE USPAT2
                8   FILE WPIDS
                8   FILE WPINDEX
L1              QUE LACTOPEROXIDASE AND OSTEO?
               ---------
                SEA L1 AND (FOOD OR DRINK OR DRUG OR FEED)
               ---------
                1   FILE BIOSIS
                1   FILE BIOTECHNO
                1   FILE CABA
                5   FILE CAPLUS
                1   FILE DGENE
                1   FILE DRUGU
                7   FILE EMBASE
                1   FILE FSTA
                2   FILE IFIPAT
                1   FILE MEDLINE
                2   FILE PROMT
                1   FILE SCISEARCH
                1   FILE TOXCENTER
              475   FILE USPATFULL
               84   FILE USPAT2
                6   FILE WPIDS
                6   FILE WPINDEX
L2              QUE L1 AND (FOOD OR DRINK OR DRUG OR FEED)
               ---------

     FILE 'BIOSIS, BIOTECHNO, CABA, CAPLUS, DGENE, DRUGU, EMBASE, FSTA,
     IFIPAT, MEDLINE, PROMT, SCISEARCH, TOXCENTER, USPATFULL, USPAT2' ENTERED
     AT 20:56:16 ON 20 JUN 2008
```

```
L3          584 S L2
L4          581 DUP REM L3 (3 DUPLICATES REMOVED)
L5          474 S L4 AND DIGEST?
L6          107 S L5 AND OSTEOBLAST?
L7          103 S L6 AND PROMOT?
L8           98 S L7 AND INDUC?
L9           28 S L8 AND OSTEOGENESIS
L10           1 S OSTEOBLAST PRODUC? AND LACTOPEROXIDASE

     FILE 'USPATFULL' ENTERED AT 21:01:45 ON 20 JUN 2008
L11           0 S LACTOPEROXIDASE IN FOOD
L12           0 S FOOD CONTAINING LACTOPEROXIDASE
L13         707 S FOOD AND LACTOPEROXIDASE
L14         191 S L13 AND (DRINK OR FEED)
L15          88 S L14 AND CONTAIN?(P)LACTOPEROXIDASE
L16          14 S L15 AND BONE

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                  30.30     112.88

STN INTERNATIONAL LOGOFF AT 21:07:22 ON 20 JUN 2008
```